Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 26.03.04 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01.08.16 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 03.05.21 |
Ryan Baker
IRC | Investor Relations Contact | - | 01.05.23 |
Nicole Sweeny
PRN | Corporate Officer/Principal | 49 | 25.07.23 |
Christopher Yea
PRN | Corporate Officer/Principal | 61 | 01.11.16 |
Mike Smith
PRN | Corporate Officer/Principal | - | 01.02.16 |
Rachel Morten
LAW | General Counsel | - | 01.01.16 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 01.02.19 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 01.08.16 |
Albert Cha
BRD | Director/Board Member | 51 | 01.01.16 |
Edward Unkart
BRD | Director/Board Member | 74 | 01.12.14 |
Nancy Stuart
BRD | Director/Board Member | 65 | 18.03.21 |
Patrick Treanor
BRD | Director/Board Member | - | 26.05.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 42 188 296 | 41 706 792 ( 98,86 %) | 0 | 98,86 % |
Unternehmenskontakt
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway Suite 901 East
02142, Cambridge
+857 999 0075
http://www.kalvista.comSektor
% 1. Jan. | Kap. | |
---|---|---|
-2,32 % | 92,59 Mrd. | |
+3,68 % | 41,43 Mrd. | |
-10,90 % | 33,49 Mrd. | |
-19,56 % | 14,62 Mrd. | |
-9,06 % | 12,77 Mrd. | |
-11,34 % | 11,58 Mrd. | |
-43,53 % | 11,35 Mrd. | |
+3,75 % | 8,97 Mrd. | |
-6,32 % | 8,3 Mrd. |